13 March 2018, 02:12
French scientists have created a drug alirocoumab, which reduces the level of “bad” cholesterol in the blood and reduces the risk of stroke and heart attack by 15 percent. In the group of patients at high risk of premature death, his reception contributed to an increase in life expectancy. Information of the relevant nature is included in the press release MedicalXpress . It also reduces the risk of premature death, significantly increasing life expectancy. Due to the medicine, the vessels and arteries were more effectively released from low-density lipoproteins – the main culprits for failures in the cardiovascular system. It belongs to the class of so-called PCSK9 inhibitors, which are monoclonal antibodies that cause an attack on a particular protein of the liver from the side of the immune system. Moreover, in the group of patients with high cholesterol, who took a new drug for 2 years, the mortality rate decreased by almost a third. In addition, high-density lipoproteins (HDL) are carriers of “good” cholesterol, which helps reduce the risk of stroke, atherosclerosis and heart attack. According to the latest information from the Medical Forum, in the process of another scientific project, specialists concluded that the risk of suffering from a heart attack increases sharply due to the increase in fat deposits in the waist region.